Belgium· BE-AMP-SAM233721-00

Ceprotin 500 IU

A protein c product containing protein c, registered in Belgium by Takeda Manufacturing Austria. The same ATC class is registered in 9 of our 19 countries.

ATC B01AD12

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedCeprotin 500 IUATCB01AD12REGISTER NO.BE-AMP-SAM233721-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Protein c is registered in 9 of 19 countries.

Countries holding a registration under ATC B01AD12 (protein c), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 6 of them publish a price we can compare per daily dose

Protein c · ATC B01AD12

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Protein C
Manufacturer
Takeda Manufacturing Austria
Country
Belgium (BE)
ATC code
B01AD12
ATC class
Protein C
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0773051
  • be_apb
    1756915

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

34 interactions on record for protein c.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Protein c · interactions on record

34 records

  • 1 severe
  • 33 moderate

Most severe, free to view

  • CaplacizumabB01AX07severe
  • DicoumarolB01AA01moderate
  • WarfarinB01AA03moderate
  • HeparinB01AB01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/59c81aa0-33d6-4fa7-aa52-a36e70b34b78
GET /v1/drugs/59c81aa0-33d6-4fa7-aa52-a36e70b34b78?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder and solvent for solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Ceprotin 500 IU",
  "name_fr": "Ceprotin 500 IU",
  "name_nl": "Ceprotin 500 IU",
  "amp_code": "SAM233721-00",
  "strengths": [
    "100.0000",
    "100.0000",
    "44.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Protein C",
    "Sodium Chloride"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Protein C",
  "authorisation_numbers": [
    "EU/1/01/190/001"
  ]
}

See everything about protein c.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.